HYLORIS PHARMACEUTIC

HYL
Real-time Quote. Real-time  - 05/27 09:58:08 am
15.1EUR +1.07%

Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in Interstitial Cystitis

12/17/2021 | 01:00am
HylorisPharmaceuticals SA announced that it has entered into a strategic collaboration with Vaneltix Pharma Inc. for the development and commercialisation of AlenuraTM as first-line drug treatment for acute pain in interstitial cystitis /bladder pain syndrome (IC/BPS). AlenuraTM is a patented, innovative, clinical-stage bladder instillation product candidate that combines lidocaine, a well-established anaesthetic, in a new alkalinized form with heparin, a component of mucous membranes2. The novel dual mode-of-action, AlenuraTM has the unique potential to i) immediately relieve pain, and ii) augment the mucous layer of the bladder. In previous clinical studies, AlenuraTM was well-tolerated and demonstrated to be more effective in terms of pain relief, urgency response and improvement of symptoms compared to placebo, and lidocaine alone3.
© S&P Capital IQ 2022
Copier lien
All news about HYLORIS PHARMACEUTICALS SA
04/01
03/31
03/31
03/16
03/16